Seminar Detail
2-Day Conference: Using the DSM-5® and ICD-10 The Changing Diagnosis of Mental Disorders AND Psychopharmacological Interventions for DSM-5® Mental Disorders: A Seminar for Mental Health Professionals
- Where:
- SALT LAKE CITY, UT
- When:
- Thursday, December 12, 2013 - Friday, December 13, 2013
This event is not currently available for purchase.
For more information: Call (800) 844-8260
Course Description:
Day 1:
The DSM-5® manual, released in May 2013, requires substantial changes in the classification and diagnosis of mental disorders. These changes reflect the explosion of new information in psychopathology, neuroscience, and treatment over the past 15 years plus the need for a stronger link to the International Classification of Diseases (ICD).
This seminar specifically emphasizes changes from the DSM-IV® to DSM-5®. You will walk through the DSM-5®manual and highlight the revisions, new diagnoses, and new specifiers that are most relevant to your daily practice. Information about the ICD-10, designated to be HIPAA’s official code book for mental disorder in 2014, will also be integrated throughout. Case examples and case studies will help you transition from making DSM-IV® multi-axial diagnosis (Axis-I-V) to effective diagnosis with the DSM-5® and ICD-10 coding systems without axis.
Day 2:
Substantial numbers of clients with DSM-5® diagnoses will be treated with a combination of psychological and pharmacological treatments. Newer drugs are being introduced to treat mental disorders based on better understanding of the neurobiological contributions to mental disorders and the latest pharmacological research.
This seminar will update and increase your understanding of:
Specifics of the pharmacological treatment and drugs of choice for the DSM-5® Depressive, Bipolar, Schizophrenia Spectrum, Anxiety, OCD, Sleep-Wake, ADHD and Neurocognitive disorders will also be discussed. Unique to this seminar is information on the common types of psychotherapeutic drugs that client’s abuse (prescription drug abuse) and methods for prevention and early detection.
Day 1:
The DSM-5® manual, released in May 2013, requires substantial changes in the classification and diagnosis of mental disorders. These changes reflect the explosion of new information in psychopathology, neuroscience, and treatment over the past 15 years plus the need for a stronger link to the International Classification of Diseases (ICD).
This seminar specifically emphasizes changes from the DSM-IV® to DSM-5®. You will walk through the DSM-5®manual and highlight the revisions, new diagnoses, and new specifiers that are most relevant to your daily practice. Information about the ICD-10, designated to be HIPAA’s official code book for mental disorder in 2014, will also be integrated throughout. Case examples and case studies will help you transition from making DSM-IV® multi-axial diagnosis (Axis-I-V) to effective diagnosis with the DSM-5® and ICD-10 coding systems without axis.
Day 2:
Substantial numbers of clients with DSM-5® diagnoses will be treated with a combination of psychological and pharmacological treatments. Newer drugs are being introduced to treat mental disorders based on better understanding of the neurobiological contributions to mental disorders and the latest pharmacological research.
This seminar will update and increase your understanding of:
- The neurobiological underpinnings of major DSM-5® diagnoses
- The types and effects of drugs used to treat these diagnoses
- The responsibilities of the non-prescribing therapist to clients taking psychiatric medication
Specifics of the pharmacological treatment and drugs of choice for the DSM-5® Depressive, Bipolar, Schizophrenia Spectrum, Anxiety, OCD, Sleep-Wake, ADHD and Neurocognitive disorders will also be discussed. Unique to this seminar is information on the common types of psychotherapeutic drugs that client’s abuse (prescription drug abuse) and methods for prevention and early detection.
12/12/13
Day 1: Using the DSM-5® and ICD-10: The Changing Diagnosis of Mental Disorders 01/01/01
12/13/13
Day 2: Psychopharmacological Interventions for DSM-5® Mental Disorders: A Seminar for Mental Health Professionals
DSM and DSM 5 are registered trademarks of the American Psychiatric Association. The American Psychiatric Association is not affiliated with nor endorses this seminar. For further information, please visit www.dsm5.org.
Objectives:
Day 1:
Day 2:
Day 1:
- Identify the major revisions in DSM-5® to substance, mood, anxiety, and other common categories of mental disorders.
- Describe five changes in the organization of mental disorder categories in the DSM-5®.
- Discuss the diagnostic criteria for six or more new diagnoses in the DSM-5®.
- Describe the ICD and its relationship to the DSM-5® in classifying mental disorders.
- Convert a DSM-IV-TR® Axis I diagnosis (name, code and specifiers) to a DSM-5® diagnosis (name, code and specifiers) and apply an ICD-10 code.
- Utilize the DSM-5® criteria to diagnose clients in case studies during the workshop.
Day 2:
- Identify neurotransmitter systems and neuroanatomy underlying the biological basis.
- Describe the major classes of drugs used to treat mental disorders.
- Outline evidence-based guidelines for the use of specific medications for commonly occurring DSM-5® mental disorders.
- Compare and contrast the effects and side effects of antipsychotics, anti-depressants, benzodiazepines and other anxiolytics, anticonvulsants and drugs used to treat other mental disorders.
- Discuss the abuse liability of drugs used in the treatment of anxiety, insomnia, pain, and ADHD.
- Explain the role of clinicians with clients receiving psychotherapeutic medications as well as psychotherapy.
MARGARET BLOOM, PHD
Margaret (Peggy) L. Bloom, PhD, Professor Emerita, Counselor Education and Counseling Psychology, Marquette University, Milwaukee, Wisconsin is a licensed psychologist and NCC certified counselor. Dr. Bloom is nationally recognized for her knowledge and expertise in assessment, DSM diagnosis, and counselor education. She is past chair and member of the board of directors of the Center for Credentialing & Education (NBCC), an elected fellow of the American Psychological Association (APA) and past president of the Association for Counselor Education and Supervision (ACES). Beginning her career as a psychiatric nurse and earning graduate degrees in nursing, counseling and a PhD in counseling psychology, Peggy brings a unique interdisciplinary perspective to each seminar. She has published numerous journal articles and presented professional education seminars across the world on assessment, diagnosis and counselor education.
Speaker Disclosures:
Financial: Dr. Margaret Bloom is a partner in Psycho-Pharm-Legal Consultants. She receives a speaking honorarium and recording royalties from PESI, Inc. She has no relevant financial relationships with ineligible organizations.
Non-financial: Dr. Margaret Bloom serves as a guest reviewer for The Clinical Supervisor and as a chair in the peer evaluations corps, Higher Learning Commission. She is a member of the American Counseling Association, the American Psychological Association, and the Association for Counselor Education and Supervision.
Speaker Disclosures:
Financial: Dr. Margaret Bloom is a partner in Psycho-Pharm-Legal Consultants. She receives a speaking honorarium and recording royalties from PESI, Inc. She has no relevant financial relationships with ineligible organizations.
Non-financial: Dr. Margaret Bloom serves as a guest reviewer for The Clinical Supervisor and as a chair in the peer evaluations corps, Higher Learning Commission. She is a member of the American Counseling Association, the American Psychological Association, and the Association for Counselor Education and Supervision.
ALAN S. BLOOM, PHD
Alan S. Bloom, PhD, is Professor Emeritus of Pharmacology and Toxicology at the Medical College of Wisconsin where he taught psychopharmacology to medical students and neuroscience graduate students. He earned a joint PhD in psychology and pharmacology and consults regularly with psychiatrists and attorneys in drug abuse and other pharmacology related cases.
Dr. Bloom has conducted extensive research on the impact of drugs of abuse (marijuana, cocaine, etc.) on the brain through use of functional magnetic resonance imaging (fMRI). His studies have been funded by the NIH and other national organizations and reported in an extensive number of publications and presentations. Dr. Bloom has served on the NIDA Center grant review panel and is an appointed member of the Controlled Substance Board of the State of Wisconsin.
Dr. Bloom is a strong and experienced presenter providing lively, information-packed seminars. He encourages the active learning of participants through application of the material in case studies and problem-based learning. In 1997 he was elected to membership in the Medical College of Wisconsin Society of Teaching Scholars.
Speaker Disclosures:
Financial: Dr. Alan Bloom receives a speaking honorarium and recording royalties from PESI, Inc. Dr. Bloom has no relevant financial relationships with ineligible organizations.
Non-financial: Dr. Alan Bloom is the Vice Chair of the State of Wisconsin Controlled Substances Board.
Credits listed below are for full attendance at the live event only. After attendance has been verified, pre-registered attendees will receive an email from PESI Customer Service with the subject line, “Evaluation and Certificate” within one week. This email will contain a link to complete the seminar evaluation and allow attendees to print, email or download a certificate of completion if in full attendance. For those in partial attendance (arrived late or left early), a letter of attendance is available through that link and an adjusted certificate of completion reflecting partial credit will be issued within 30 days (if your board allows). Please see “live seminar schedule” for full attendance start and end times. NOTE: Boards do not allow credit for breaks or lunch.
If your profession is not listed, please contact your licensing board to determine your continuing education requirements and check for reciprocal approval. For other credit inquiries not specified below, or questions on home study credit availability, please contact cepesi@pesi.com or 800-844-8260 before the event.
Materials that are included in this course may include interventions and modalities that are beyond the authorized practice of mental health professionals. As a licensed professional, you are responsible for reviewing the scope of practice, including activities that are defined in law as beyond the boundaries of practice in accordance with and in compliance with your professions standards.
The planning committee and staff who controlled the content of this activity have no relevant financial relationships to disclose. For speaker disclosures, please see speaker bios.
PESI, Inc. offers continuing education programs and products under the brand names PESI, PESI Healthcare, PESI Kids, PESI Rehab and Psychotherapy Networker.
If your profession is not listed, please contact your licensing board to determine your continuing education requirements and check for reciprocal approval. For other credit inquiries not specified below, or questions on home study credit availability, please contact cepesi@pesi.com or 800-844-8260 before the event.
Materials that are included in this course may include interventions and modalities that are beyond the authorized practice of mental health professionals. As a licensed professional, you are responsible for reviewing the scope of practice, including activities that are defined in law as beyond the boundaries of practice in accordance with and in compliance with your professions standards.
The planning committee and staff who controlled the content of this activity have no relevant financial relationships to disclose. For speaker disclosures, please see speaker bios.
PESI, Inc. offers continuing education programs and products under the brand names PESI, PESI Healthcare, PESI Kids, PESI Rehab and Psychotherapy Networker.
Satisfaction Guarantee
Your satisfaction is our goal and our guarantee. Concerns should be addressed to PESI Rehab, P.O. Box 1000, Eau Claire, WI 54702-1000 or call (800) 844-8260.
ADA Needs
We would be happy to accommodate your ADA needs; please call our Customer Service Department for more information at (800) 844-8260.
Your satisfaction is our goal and our guarantee. Concerns should be addressed to PESI Rehab, P.O. Box 1000, Eau Claire, WI 54702-1000 or call (800) 844-8260.
ADA Needs
We would be happy to accommodate your ADA needs; please call our Customer Service Department for more information at (800) 844-8260.
Credit Card Required for online registration | Contact us to redeem Gift Certificates